摘要目的 比较新辅助放化疗( NCRT)和新辅助化疗( NCT)联合手术对食管癌生存的影响.方法 回顾分析2011－2015年确诊的行新辅助治疗联合手术治疗的胸段食管鳞癌275例资料.NCRT组70例,NCT组205例.采用Kaplan-Meier法计算生存率,Logrank法对比生存,Cox回归模型多因素分析.结果 中位随访时间32(3～84)个月.全组中位生存、中位无复发生存期分别为42 (3～84)、30(3～84)个月,3、5年总生存率分别为56. 8%、45. 9%,3、5年无复发生存率分别为45. 1%、38. 9%. NCRT和NCT组患者中位生存期分别为46(7～84)个月和40(4～74)个月,中位无复发生存期分别为31(3～84)个月和28(3～69)个月;3、5年总生存率分别为59. 1%、47. 1%和56. 3%、47. 5%(P＝0. 515),3、5年无复发生存率分别为44. 5%、40. 1%和47%、39%( P＝0. 554).多因素分析显示术后病理TNM分期是影响食管癌预后的独立因素( P＝0. 001).结论 NCRT与NCT联合手术治疗生存结果相似,术后病理分期是独立的生存影响因素.

abstractsObjective To compare the effect of neoadjuvant chemoradiotherapy ( NCRT ) and neoadjuvant chemotherapy ( NCT) on the survival of patients with esophageal cancer. Methods Clinical data of 275 cases of thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were analyzed retrospectively. The data of treatment and follow-up were complete and analyzable. There were 70 cases in the NCRT group and 205 cases in the NCT group. The survival rate was calculated by Kaplan-Meier method and statistically compared by log-rank test, and multivariate analysis was performed by Cox regression model. Results The median follow-up time was 32( 3-84) months. The median survival time and recurrence-free survival time was 42( 3-84) months and 30 ( 3-84) months, respectively. The overall 3-and 5-year survival rates were 56. 8% and 45. 9%, respectively, and the 3-and 5-year recurrence-free survival rates were 45. 1% and 38. 9%, respectively. The median survival time in the NCRT and NCT groups was 46( 7-84) and 40( 4-74) months, and the median recurrence-free survival time was 31( 3-84) and 28( 3-69) months, respectively. The 3-and 5-year overall survival of the two groups were 59. 1%, 47. 1% and 56. 3%, 47. 5%( P＝0. 515) , and the 3-and 5-year recurrence-free survival were 44. 5%, 40. 1% and 47%, 39%, respectively. There was no significant difference in the survival between two neoadjuvant therapy modes ( P＝ 0. 554 ) . Multivariate analysis showed that postoperative pathological TNM staging was an independent factor affecting the prognosis of patients with esophageal cancer ( P＝0. 001) . Conclusions The survival results of NCRT are similar to those of NCT. Postoperative pathological staging is an independent survival factor.